Izrael - angielski - Ministry of Health

teva pharmaceutical industries ltd, israel - acetylsalicylic acid - tablets enteric coated - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

Izrael - angielski - Ministry of Health

teva pharmaceutical industries ltd, israel - acetylsalicylic acid - tablets enteric coated - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

Izrael - angielski - Ministry of Health

rafa laboratories ltd - fingolimod as hydrochloride - capsules - fingolimod as hydrochloride 0.5 mg - fingolimod - treatment of patients with relapsing forms of multiple sclerosis (ms) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

Izrael - angielski - Ministry of Health

bayer israel ltd - levonorgestrel - film coated tablets - levonorgestrel 0.03 mg - levonorgestrel - oral contraception.

Izrael - angielski - Ministry of Health

bayer israel ltd - riociguat - film coated tablets - riociguat 0.5 mg - riociguat - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii with • inoperable cteph, • persistent or recurrent cteph after surgical treatment, to improve exercise capacity. pulmonary arterial hypertension (pah)adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity.efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

Izrael - angielski - Ministry of Health

bayer israel ltd - riociguat - film coated tablets - riociguat 0.5 mg - riociguat - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii with • inoperable cteph, • persistent or recurrent cteph after surgical treatment, to improve exercise capacity. pulmonary arterial hypertension (pah)adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity.efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

Izrael - angielski - Ministry of Health

bayer israel ltd - riociguat - film coated tablets - riociguat 1 mg - riociguat - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii with • inoperable cteph, • persistent or recurrent cteph after surgical treatment, to improve exercise capacity. pulmonary arterial hypertension (pah)adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity.efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

Izrael - angielski - Ministry of Health

bayer israel ltd - riociguat - film coated tablets - riociguat 1 mg - riociguat - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii with • inoperable cteph, • persistent or recurrent cteph after surgical treatment, to improve exercise capacity. pulmonary arterial hypertension (pah)adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity.efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

Izrael - angielski - Ministry of Health

bayer israel ltd - riociguat - film coated tablets - riociguat 1.5 mg - riociguat - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii with • inoperable cteph, • persistent or recurrent cteph after surgical treatment, to improve exercise capacity. pulmonary arterial hypertension (pah)adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity.efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

Izrael - angielski - Ministry of Health

bayer israel ltd - riociguat - film coated tablets - riociguat 1.5 mg - riociguat - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii with • inoperable cteph, • persistent or recurrent cteph after surgical treatment, to improve exercise capacity. pulmonary arterial hypertension (pah)adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity.efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.